This company is no longer active
DP80 Stock Overview
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Diffusion Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.97 |
52 Week High | US$15.08 |
52 Week Low | US$5.67 |
Beta | 1.76 |
1 Month Change | 31.11% |
3 Month Change | 0% |
1 Year Change | -47.16% |
3 Year Change | -92.47% |
5 Year Change | n/a |
Change since IPO | -76.24% |
Recent News & Updates
Recent updates
Shareholder Returns
DP80 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 12.7% | 4.2% | -0.6% |
1Y | -47.2% | -13.8% | 4.9% |
Return vs Industry: DP80 underperformed the German Biotechs industry which returned -9.3% over the past year.
Return vs Market: DP80 underperformed the German Market which returned 2.1% over the past year.
Price Volatility
DP80 volatility | |
---|---|
DP80 Average Weekly Movement | 7.3% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 9.6% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DP80's share price has been volatile over the past 3 months.
Volatility Over Time: DP80's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 13 | Bob Cobuzzi | https://www.diffusionpharma.com |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc. Fundamentals Summary
DP80 fundamental statistics | |
---|---|
Market cap | €14.24m |
Earnings (TTM) | -€12.03m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs DP80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DP80 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$13.08m |
Earnings | -US$13.08m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.41 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DP80 perform over the long term?
See historical performance and comparison